Tatva Chintan Pharma Chem cash flow

Latest FY26

Cash from operations: ₹31.5cr+27.6% on FY25
Capital spending: ₹114cr+49.2% on FY25
Free cash flow: −₹82.3cr−₹51.6 cr in FY25
Cash from financing: ₹78.9cr+376.5% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	36.8	27.7	25.6	9.6
	—	2.9	1.3	6.5	8.4
	—	−0.7	−0.5	−3.3	−5.3
	—	0.0	0.0	−0.2	0.0
	—	2.0	−0.0	−0.4	3.6
	—	3.1	0.9	0.3	4.5
	—	−0.0	−0.1	−0.0	0.0
	—	−62.1	18.8	9.7	7.5
	—	−21.5	−15.2	15.4	−31.4
	—	0.6	−0.1	2.2	0.5
	—	−0.3	−0.0	−1.6	−0.8
	—	−3.5	−6.2	−2.1	19.4
	—	−0.2	−0.3	−0.3	−0.0
	—	19.7	−13.1	11.2	−12.7
	—	−0.3	0.0	−0.3	−8.9
	—	4.4	8.1	1.2	−2.7
	—	0.0	0.0	0.0	0.0
	—	0.1	0.1	0.0	0.2
	—	1.2	0.1	0.2	0.5
Cash from operating activities
	84.3	57.0	7.6	43.6	44.8
	—	−17.8	21.6	64.3	−7.7
	—	39.2	29.2	108	37.1
	—	7.7	4.5	9.9	9.3
	—	31.5	24.7	98.0	27.8
Cash from investing activities
	—	114	76.3	129	203
	—	0.4	0.1	0.2	0.1
	—	1.4	0.0	0.0	0.0
	—	0.8	0.5	3.3	5.3
	—	−4.7	10.4	4.5	96.6
	—	−116	−65.3	−121	−101
Cash from financing activities
	—	0.0	0.0	197	0.0
	—	84.6	25.7	−146	64.6
	—	0.6	3.2	8.6	13.9
	—	2.7	1.3	6.5	8.4
	—	2.3	4.7	4.7	4.4
	—	−0.0	0.0	−0.1	−0.0
	—	78.9	16.6	30.5	37.8
	—	−5.4	−24.0	8.0	−35.6
	—	−0.2	0.1	−0.1	−0.1
	—	−5.6	−23.9	7.9	−35.7
	—	—	—	35.3	27.4
Reference items
	127	93.2	34.2	68.2	60.6
	19.5%	18.4%	8.9%	17.3%	14.3%
	−82.3	−82.3	−51.6	−30.5	−175
	—	−1.0	−30.8	−193	—
	−₹35.18	−₹35.18	−₹22.06	−₹13.03	−₹74.95
	—	0.75×	4.32×	3.23×	0.61×
	—	7.7	4.5	9.9	9.3
	—	2.7	1.3	6.5	8.4

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

TATVA₹1,614.80

Tatva Chintan Pharma Chem Limited

· Chemicals

₹ CrorePeersVISHNU JUBLCPL KIRIINDUS FOSECOIND CHEMPLASTS DDEVPLSTIK GUJALKALI YASHOMcap ₹3,777 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	9.6	25.6	27.7	36.8	—
+ Finance Costs	8.4	6.5	1.3	2.9	—
+ Interest Income	-5.3	-3.3	-0.5	-0.7	—
+ Fair Value (Gains) / Losses	0.0	-0.2	0.0	0.0	—
+ Unrealised FX (Gain) / Loss	3.6	-0.4	-0.0	2.0	—
+ Other Non-cash Items	4.5	0.3	0.9	3.1	—
+ Other — Cash Effects are Investing / Financing	0.0	-0.0	-0.1	-0.0	—
Changes in Working Capital
+ Inventories	7.5	9.7	18.8	-62.1	—
+ Trade Receivables — Current	-31.4	15.4	-15.2	-21.5	—
+ Other Financial Assets — Current	0.5	2.2	-0.1	0.6	—
+ Other Financial Assets — Non-current	-0.8	-1.6	-0.0	-0.3	—
+ Other Current Assets	19.4	-2.1	-6.2	-3.5	—
+ Other Non-current Assets	-0.0	-0.3	-0.3	-0.2	—
+ Trade Payables — Current	-12.7	11.2	-13.1	19.7	—
+ Other Financial Liabilities — Current	-8.9	-0.3	0.0	-0.3	—
+ Other Current Liabilities	-2.7	1.2	8.1	4.4	—
+ Other Non-current Liabilities	0.0	0.0	0.0	0.0	—
+ Provisions — Current	0.2	0.0	0.1	0.1	—
+ Provisions — Non-current	0.5	0.2	0.1	1.2	—
Cash from Operating Activities
Profit Before Tax (per I/S)	44.8	43.6	7.6	57.0	84.3
+ Total Adjustments (incl. Working Capital)	-7.7	64.3	21.6	-17.8	—
Cash from Operations (pre-tax)	37.1	107.9	29.2	39.2	—
+ Income Taxes Paid	9.3	9.9	4.5	7.7	—
Cash from Operating Activities	27.8	98.0	24.7	31.5	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	203.1	128.5	76.3	113.8	—
+ Disp of Fixed Assets	0.1	0.2	0.1	0.4	—
+ Government Grants Received	0.0	0.0	0.0	1.4	—
+ Interest Received — Investing	5.3	3.3	0.5	0.8	—
+ Other Inflows / (Outflows) — Investing	96.6	4.5	10.4	-4.7	—
Cash from Investing Activities	-101.1	-120.5	-65.3	-115.8	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	196.6	0.0	0.0	—
+ Proceeds from Borrowings	64.6	-146.2	25.7	84.6	—
+ Repayment of Borrowings	13.9	8.6	3.2	0.6	—
+ Interest Paid	8.4	6.5	1.3	2.7	—
+ Dividends Paid	4.4	4.7	4.7	2.3	—
+ Other Inflows / (Outflows) — Financing	-0.0	-0.1	0.0	-0.0	—
Cash from Financing Activities	37.8	30.5	16.6	78.9	—
Net Changes in Cash (pre-FX)	-35.6	8.0	-24.0	-5.4	—
+ Effect of FX Rate Changes on Cash	-0.1	-0.1	0.1	-0.2	—
Net Changes in Cash	-35.7	7.9	-23.9	-5.6	—
Closing Cash	27.4	35.3	—	—	—
Reference Items
EBITDA	60.6	68.2	34.2	93.2	126.6
EBITDA Margin %	14.30	17.33	8.94	18.42	19.48
Free Cash Flow (CFO − Capex)	-175.3	-30.5	-51.6	-82.3	-82.3
Free Cash Flow to Equity	—	-193.0	-30.8	-1.0	—
Free Cash Flow per Basic Share	-74.95	-13.03	-22.06	-35.18	-35.18
Cash Flow to Net Income	0.61	3.23	4.32	0.75	—
Cash Paid for Taxes	9.3	9.9	4.5	7.7	—
Cash Paid for Interest	8.4	6.5	1.3	2.7	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.